West Pharmaceutical stock gains as UBS lifts price target to USD 415

West Pharmaceutical Services stock (ISIN US9523901012) has drawn fresh investor interest after UBS reaffirmed its Buy rating and raised its price target to USD 415 on September 9, 2026, signaling confidence in the company’s growth trajectory based on its latest financial performance.

UBS raises target and highlights valuation

According to Benzinga on September 9, 2026, UBS has reiterated its Buy rating on West Pharmaceutical Services and lifted its price target from USD 340 to USD 415, an increase of 22.1 percent that underscores the broker’s view of further upside potential.

As GuruFocus reported on September 9, 2026, UBS’s new USD 415 target implies that the shares are about 22.1 percent above the prior target of USD 340 and positions the stock modestly above a cited intrinsic value estimate of USD 357.62, where West Pharmaceutical was described as roughly 5.2 percent undervalued versus that benchmark at a share price of USD 339.09.

The latest analyst move comes after a period of strong share-price performance and solid operating trends; UBS’s decision to maintain a positive stance while increasing the target suggests that the broker sees the valuation as still justified by the company’s earnings outlook and margin profile, even after the stock’s climb over the past year.

Recent price level and trading range

In trading on September 9, 2026, West Pharmaceutical Services stock was reported at USD 338.79 on the New York Stock Exchange, with intraday trading volume of 23,467 shares against an average volume of 840,700, highlighting relatively calm trading activity on that day compared to typical turnover.

According to MarketBeat on September 9, 2026, West Pharmaceutical Services has a 52-week low of USD 223.83 and a 52-week high of USD 386.00, placing the quoted price of USD 338.79 roughly USD 115 above the yearly low and about USD 47 below the yearly high, a corridor that shows how far the stock has rebounded from last year’s trough while still leaving room before retesting its peak.

The same MarketBeat overview notes a market capitalization of USD 23.84 billion for West Pharmaceutical Services as of September 9, 2026, with a price-earnings ratio of 43.49 and a PEG ratio of 2.38, indicating that investors are paying a premium multiple for the company’s expected growth but that this valuation is still seen as supported by consensus earnings forecasts.

Fundamentals from the latest reporting period

According to GuruFocus, West Pharmaceutical Services has been posting robust results in its most recent reported periods, with the analysis citing earnings that support the elevated valuation and contributing to the positive stance taken by UBS; while exact quarterly revenue and earnings figures are not detailed in that snapshot, the commentary links the higher price target directly to expectations of continued growth and margin resilience in the latest fiscal year and recent quarters.

For investors, one of the key points in the UBS and GuruFocus analysis is the relationship between the share price and the estimated intrinsic value: at a recent share price just under USD 340, West Pharmaceutical was assessed at about 5.2 percent below a modeled fair value of USD 357.62, implying that the broker’s new USD 415 target builds in upside of roughly USD 75 over that intrinsic value yardstick and reflects confidence that future reported earnings can close this gap.

Given the premium price-earnings ratio of 43.49 cited by MarketBeat for September 9, 2026, the market is clearly assigning a high value to West Pharmaceutical’s ability to generate consistent earnings growth; the key question for the coming quarters will be whether revenue and profit expansion from its latest interim and full-year reports can keep pace with these expectations so that the elevated multiples remain justified.

Analyst coverage and investor perspective

As MarketBeat explains, West Pharmaceutical Services shares are now covered by analysts at UBS Group, who have set the USD 415 price target alongside their Buy rating, formally adding the company to the broker’s coverage universe and reinforcing the visibility of the stock among institutional investors.

The GuruFocus note on September 9, 2026, highlights that UBS’s revised target represents a notable 22.1 percent increase from the earlier USD 340 level, an adjustment that often reflects both a reassessment of the company’s recent financial performance and a more optimistic view of its earnings trajectory over the next several reporting periods, including the upcoming quarters in fiscal year 2026 and beyond.

For shareholders, the combination of a high but not extreme valuation relative to growth estimates, a share price sitting comfortably above the 52-week low and below the 52-week high, and a prominent broker raising its target provides a mixed yet constructive picture: it suggests that while much of the company’s quality is already priced in, there is still meaningful potential if West Pharmaceutical can deliver on the earnings and margin profile that UBS and other analysts are modeling.

West Pharmaceutical stock and recent closing level

West Pharmaceutical Services stock last closed at around USD 338.79 on the New York Stock Exchange on September 9, 2026, placing it in the upper half of its 52-week trading range between USD 223.83 and USD 386.00 and giving the company an equity market capitalization of approximately USD 23.84 billion at that date.

More news and analyses on West Pharmaceutical stock